HC Wainwright & Co. maintains Mirum Pharmaceuticals at Buy, raises price target to $202 from $200

What happened

HC Wainwright & Co. kept its Buy rating on Mirum Pharmaceuticals and raised its price target to $202 from $200. The revised target is 1.0% higher and implies 132.1% upside from the November 3 closing price of $87.03.

Confirmed

Global impact / market context

The higher target signals that HC Wainwright sees more potential value in Mirum shares, but a price target is an analyst estimate, not a promised return. Changes in such estimates can influence investor expectations and buying or selling decisions.

Analyst inference

The recent analyst targets listed in the article range from $145 to $160, while HC Wainwright's new $202 target is higher. This shows a difference in analyst expectations, not evidence that Mirum's business results or share price have changed.

Analyst inference

What to watch

1. Watch for Mirum's next company updates and whether reported business results support the expectations behind analysts' share-price targets. Analyst inference
2. Compare future analyst ratings and targets with HC Wainwright's $202 estimate and the recent $145–$160 range reported in the article. Analyst inference
3. The article gives no reason for the target increase, so investors should not assume it reflects new clinical, sales, or financial information. Confirmed

Evidence

• Original source link unavailable